OmniAb to Participate in Upcoming Investor Conferences in November

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation in the following upcoming investor conferences: Stifel Healthcare Conference Date: Wednesday, November 11, 2026 2026 Truist Securities BioPharma Symposium Date: Thursday, November 12, 2026 Jefferies London Healthcare Conference Date: November 16–19, 2026 Craig-Hallum Investor.

Business Wire • Oct 26, 2026

OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference

OmniAb NASDAQ: OABI Chief Financial Officer Kurt Gustafson outlined the company's antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensing technology to pharmaceutical and biotechnology companies rather than developing drugs internally.

MarketBeat • Oct 25, 2026

OmniAb to Report Third Quarter 2026 Financial Results on October 30

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time. Conference Call and Webcast What:   OmniAb conf.

Business Wire • Oct 14, 2026

OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth

OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform.

MarketBeat • Oct 7, 2026

OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

Seeking Alpha • Oct 6, 2026

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Oct 6, 2026

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration® platform, and introduces the OmniTides™ peptide discovery platform and brand. “We look forward to bringing together our investment com.

Business Wire • Oct 6, 2026

OmniAb to Host Investor & Analyst Day on October 6, 2026

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA. The event will feature presentations from OmniAb's executive leadership team, including corporate updates, select partner programs, the xPloration® platform, technology innovations and a Q&A sessi.

Business Wire • Sep 14, 2026

OmniAb to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation in the following upcoming investor conferences: Nasdaq/LD Micro Summit Series Date: Wednesday, September 9, 2026 H.C. Wainwright 28th Annual Global Investment Conference Date: Tuesday, September 15, 2026 The Nasdaq/LD Micro Summit will take place at the Nasdaq Headquarters in.

Business Wire • Aug 26, 2026

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.

Seeking Alpha • Aug 18, 2026